Base de dados : MEDLINE Pesquisa : D03.633.400.811 [Categoria DeCS] Referências encontradas : 1873 [refinar] Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 188

ir para página

1 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28455257 [Au] Autor: Narang SS; Shuaib S; Goyal B [Ad] Endereço: Department of Chemistry, School of Basic and Applied Sciences, Sri Guru Granth Sahib World University, Fatehgarh Sahib 140406, Punjab, India. [Ti] Título: Molecular insights into the inhibitory mechanism of rifamycin SV against ß -microglobulin aggregation: A molecular dynamics simulation study. [So] Source: Int J Biol Macromol;102:1025-1034, 2017 Sep. [Is] ISSN: 1879-0003 [Cp] País de publicação: Netherlands [La] Idioma: eng [Ab] Resumo: Dialysis-related amyloidosis (DRA) is a severe condition characterized by the accumulation of amyloidogenic ß -microglobulin (ß m) protein around skeletal joints and bones. The small molecules that modulate ß m aggregation have been identified in vitro, however, the underlying inhibitory mechanism remain elusive. In the present study, molecular docking and molecular dynamics (MD) simulations were performed to elucidate the inhibitory mechanism of an antibiotic, rifamycin SV (C ) reported for its in vitro anti-aggregation activity against ß m. The molecular docking analysis highlight that C display hydrophobic contacts with residues in the aggregation prone region of ß m. MD simulations reveal enhanced structural stability of ß m in the presence of C . C inhibit the conformational transition of the C-terminal region of ß m from a ß-sheet to random coil conformation, which is reported for the initiation of fibrillogenesis of ß m. The results of the present study provide insight into the key interactions and underlying inhibitory mechanism of a small molecule against ß m aggregation that will help in the design and development of more potent, novel inhibitors of ß m aggregation. [Mh] Termos MeSH primário: Simulação de Dinâmica Molecular Agregados Proteicos/efeitos dos fármacos Rifamicinas/farmacologia Microglobulina-2 beta/química [Mh] Termos MeSH secundário: Conformação Proteica em Folha beta Estabilidade Proteica Termodinâmica [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Protein Aggregates); 0 (Rifamycins); 0 (beta 2-Microglobulin); DU69T8ZZPA (rifamycin SV) [Em] Mês de entrada: 1803 [Cu] Atualização por classe: 180309 [Lr] Data última revisão: 180309 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170430 [St] Status: MEDLINE

2 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28467330 [Au] Autor: Maconi G [Ad] Endereço: Gastroenterology Unit, Department of Biomedical and Clinical Sciences, L. Sacco University Hospital, Milan, Italy. giovanni.maconi@unimi.it. [Ti] Título: Diagnosis of symptomatic uncomplicated diverticular disease and the role of Rifaximin in management. [So] Source: Acta Biomed;88(1):25-32, 2017 Apr 28. [Is] ISSN: 0392-4203 [Cp] País de publicação: Italy [La] Idioma: eng [Ab] Resumo:  Patients with diverticulosis who develop persistent abdominal pain, bloating and changes in bowel habits not associated with overt inflammation may have symptomatic uncomplicated diverticular disease (SUDD). The severity and frequency of SUDD symptoms may have an impact on daily activities and severely affect quality of life. Effective management of SUDD should follow a three part strategy: divert, tackle and maintain. Divert to make the correct diagnosis: several symptoms of SUDD are common to other conditions that require different therapeutic approaches. However, several key differences should be used to diagnose SUDD. Pain in SUDD is normally in the iliac fossa, persistent, often lasting more than 24 hrs, and is not relieved by bowel movement, as is often the case with irritable bowel syndrome. Another difference is in the timing: the prevalence of SUDD increases with age, and patients under the age of 40 years are less likely to have diverticula. It is useful to establish whether a patient has diverticulosis, especially if the patient is relatively young; lack of diverticula excludes SUDD. Cross-sectional imaging is indicated; however, recent archival image data or ultrasonography may be useful alternatives. Laboratory tests should be ordered to exclude overt inflammation. Once the diagnosis of SUDD is made, the patient should receive effective therapy to tackle the condition. This should include dietary fibre supplementation and cyclic treatment with rifaximin 400 mg twice daily for 7 days per month. Once symptom control is achieved, it should be maintained by continuing therapy for at least 12 months. [Mh] Termos MeSH primário: Doenças Diverticulares/diagnóstico Doenças Diverticulares/tratamento farmacológico Fármacos Gastrointestinais/uso terapêutico Rifamicinas/uso terapêutico [Mh] Termos MeSH secundário: Dor Abdominal/tratamento farmacológico Biomarcadores/análise Proteína C-Reativa/análise Ensaios Clínicos como Assunto Constipação Intestinal/tratamento farmacológico Diagnóstico por Imagem Diarreia/tratamento farmacológico Fármacos Gastrointestinais/farmacologia Seres Humanos Complexo Antígeno L1 Leucocitário/análise Rifamicinas/farmacologia [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Biomarkers); 0 (Gastrointestinal Agents); 0 (Leukocyte L1 Antigen Complex); 0 (Rifamycins); 9007-41-4 (C-Reactive Protein); L36O5T016N (rifaximin) [Em] Mês de entrada: 1801 [Cu] Atualização por classe: 180125 [Lr] Data última revisão: 180125 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170504 [St] Status: MEDLINE [do] DOI: 10.23750/abm.v88i1.6360

3 / 1873

MEDLINE

seleciona para imprimir Fotocópia Registro de Ensaios Clínicos Texto completo

[PMID]: 27775818 [Au] Autor: Kimer N; Pedersen JS; Busk TM; Gluud LL; Hobolth L; Krag A; Møller S; Bendtsen F; Copenhagen Rifaximin (CoRif) Study Group [Ad] Endereço: Gastro Unit, Medical Division, Copenhagen University Hospital, Hvidovre, Denmark. [Ti] Título: Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. [So] Source: Hepatology;65(2):592-603, 2017 02. [Is] ISSN: 1527-3350 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: Decompensated cirrhosis is characterized by disturbed systemic and splanchnic hemodynamics. Bacterial translocation from the gut is considered the key driver in this process. Intestinal decontamination with rifaximin may improve hemodynamics. This double-blind, randomized, controlled trial (clinicaltrials.gov, NCT01769040) investigates the effects of rifaximin on hemodynamics, renal function, and vasoactive hormones. We randomized 54 stable outpatients with cirrhosis and ascites to rifaximin 550 mg twice a day (n = 36) or placebo twice a day (n = 18). Forty-five patients were male, mean age 56 years (±8.4), average Child score 8.3 (±1.3), and Model for End-Stage Liver Disease score 11.7 (±3.9). Measurements of hepatic venous pressure gradient, cardiac output, and systemic vascular resistance were made at baseline and after 4 weeks. The glomerular filtration rate and plasma renin, noradrenaline, lipopolysaccharide binding protein, troponin T, and brain natriuretic peptide levels were measured. Rifaximin had no effect on hepatic venous pressure gradient, mean 16.8 ± 3.8 mm Hg at baseline versus 16.6 ± 5.3 mm Hg at follow-up, compared to the placebo, mean 16.4 ± 4 mm Hg at baseline versus 16.3 ± 4.4 mm Hg at follow-up, P = 0.94. No effect was found on cardiac output, mean 6.9 ± 1.7 L/min at baseline versus 6.9 ± 2.3 L/min at follow-up, compared to placebo, mean 6.6 ± 1.9 L/min at baseline compared to 6.5 ±2.1 L/min at follow-up, P = 0.66. No effects on the glomerular filtration rate, P = 0.14, or vasoactive hormones were found. Subgroup analyses on patients with increased lipopolysaccharide binding protein and systemic vascular resistance below the mean (1,011 dynes × s/cm ) revealed no effect of rifaximin. CONCLUSION: Four weeks of treatment with rifaximin did not reduce the hepatic venous pressure gradient or improve systemic hemodynamics in patients with cirrhosis and ascites; rifaximin did not affect glomerular filtration rate or levels of vasoactive hormones. (Hepatology 2017;65:592-603). [Mh] Termos MeSH primário: Fármacos Gastrointestinais/uso terapêutico Hemodinâmica/efeitos dos fármacos Encefalopatia Hepática/tratamento farmacológico Cirrose Hepática/tratamento farmacológico Rifamicinas/uso terapêutico [Mh] Termos MeSH secundário: Adulto Idoso Dinamarca Relação Dose-Resposta a Droga Método Duplo-Cego Esquema de Medicação Feminino Seguimentos Taxa de Filtração Glomerular/efeitos dos fármacos Encefalopatia Hepática/etiologia Encefalopatia Hepática/fisiopatologia Hospitais Universitários Seres Humanos Hipertensão Portal/prevenção & controle Cirrose Hepática/complicações Cirrose Hepática/diagnóstico Masculino Meia-Idade Avaliação de Resultados (Cuidados de Saúde) Seleção de Pacientes Medição de Risco Índice de Gravidade de Doença Resistência Vascular/efeitos dos fármacos [Pt] Tipo de publicação: JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL; RESEARCH SUPPORT, NON-U.S. GOV'T [Nm] Nome de substância: 0 (Gastrointestinal Agents); 0 (Rifamycins); L36O5T016N (rifaximin) [Em] Mês de entrada: 1708 [Cu] Atualização por classe: 180121 [Lr] Data última revisão: 180121 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 161025 [Cl] Clinical Trial: ClinicalTrial [St] Status: MEDLINE [do] DOI: 10.1002/hep.28898

4 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28982166 [Au] Autor: Chang JY; Kim SE; Kim TH; Woo SY; Ryu MS; Joo YH; Lee KE; Lee J; Lee KH; Moon CM; Jung HK; Shim KN; Jung SA [Ad] Endereço: Departments of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea. [Ti] Título: Emergence of rifampin-resistant staphylococci after rifaximin administration in cirrhotic patients. [So] Source: PLoS One;12(10):e0186120, 2017. [Is] ISSN: 1932-6203 [Cp] País de publicação: United States [La] Idioma: eng [Ab] Resumo: OBJECTIVES: Rifaximin, a poorly absorbed antibiotics, has gut-specific therapeutic effects. Although frequently prescribed to manipulate intestinal luminal bacterial population in various diseases, the possible induction of antibacterial cross-resistance to a target pathogen is a major concern in long-term rifaximin administration. We aimed to evaluate whether rifampin-resistant staphylococci could evolve after rifaximin treatment in cirrhotic patients. METHOD: A total of 25 cirrhotic patients who were administered rifaximin for the prevention of hepatic encephalopathy were enrolled. Swabs from both hands and the perianal skin were acquired on day 0 (before rifaximin treatment), period 1 (1-7 weeks after treatment), and period 2 (8-16 weeks after treatment) the staphylococcal strain identification and rifampin-resistance testing. RESULTS: A total of 198 staphylococcal isolates from 15 species were identified. Staphylococcus epidermidis was isolated most frequently, and Staphylococcus haemolyticus was the most common resistant species both from hands and perianal skin. Eleven patients (44.0%) developed rifampin-resistant staphylococcal isolates in period 1. Among these patients, only six (54.5%) were found to have rifampin-resistant isolates in period 2, with no significant infectious events. Rifampin-resistant staphylococcal isolates were more frequently found in perianal skin than from the hands. No patients acquired a newly resistant strain in period 2. CONCLUSIONS: About one-half of cirrhotic patients in this study developed rifampin-resistant staphylococcal isolates after rifaximin treatment. Although the resistant strains were no longer detected in about half of the patients in the short-term, the long-term influence of this drug treatment should be determined. [Mh] Termos MeSH primário: Cirrose Hepática/tratamento farmacológico Rifampina/farmacologia Rifamicinas/administração & dosagem Staphylococcus/efeitos dos fármacos [Mh] Termos MeSH secundário: Idoso Resistência Microbiana a Medicamentos Feminino Seres Humanos Masculino Testes de Sensibilidade Microbiana Meia-Idade [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Rifamycins); L36O5T016N (rifaximin); VJT6J7R4TR (Rifampin) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171103 [Lr] Data última revisão: 171103 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 171006 [St] Status: MEDLINE [do] DOI: 10.1371/journal.pone.0186120

5 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28697313 [Au] Autor: Lin SW; Lin CJ; Yang JC [Ad] Endereço: a Graduate Institute of Clinical Pharmacy, College of Medicine , National Taiwan University , Taipei , Taiwan. [Ti] Título: Rifamycin SV MMX for the treatment of traveler's diarrhea. [So] Source: Expert Opin Pharmacother;18(12):1269-1277, 2017 Aug. [Is] ISSN: 1744-7666 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: INTRODUCTION: Rifamycin SV MMX®, a non-absorbable rifamycin antibiotic formulated using the multi-matrix system, was designed to exhibit its pharmacological action on the distal small intestine and colon. Its clinical efficacy and safety profile in the treatment of traveler's diarrhea were evaluated in several clinical studies. Areas covered: This review summarizes all available evidence regarding clinical trials of the efficacy and safety profile of rifamycin SV MMX for the treatment of traveler's diarrhea. Expert opinion: Rifamycin SV MMX demonstrated an excellent pharmacokinetic profile with decreased systemic toxicity similar to rifaximin. In phase II and phase III clinical trials, concerns have been raised regarding the medicine's efficacy in terms of the time to last unformed stool and cure rate compared to current recommended antibiotics in the treatment of acute diarrhea caused by diarrheagenic Escherichia coli and invasive pathogens. The significance of the increase in MICs after the use of rifamycin SV MMX warrants further examination. [Mh] Termos MeSH primário: Antibacterianos/uso terapêutico Diarreia/tratamento farmacológico Rifamicinas/uso terapêutico Viagem [Mh] Termos MeSH secundário: Antibacterianos/farmacocinética Ensaios Clínicos como Assunto Diarreia/microbiologia Seres Humanos Testes de Sensibilidade Microbiana Rifamicinas/farmacocinética Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Rifamycins); DU69T8ZZPA (rifamycin SV) [Em] Mês de entrada: 1711 [Cu] Atualização por classe: 171106 [Lr] Data última revisão: 171106 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170712 [St] Status: MEDLINE [do] DOI: 10.1080/14656566.2017.1353079

6 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28626122 [Au] Autor: Tamaoki S; Sato I [Ti] Título: Pharmacological properties and clinical findings of rifaximin (RIFXIMA TABLETS 200 mg). [So] Source: Nihon Yakurigaku Zasshi;149(6):288-295, 2017. [Is] ISSN: 0015-5691 [Cp] País de publicação: Japan [La] Idioma: jpn [Mh] Termos MeSH primário: Antibacterianos/farmacologia Rifamicinas/farmacologia [Mh] Termos MeSH secundário: Animais Antibacterianos/uso terapêutico Ensaios Clínicos como Assunto Encefalite por Herpes Simples/tratamento farmacológico Seres Humanos Viabilidade Microbiana/efeitos dos fármacos Rifamicinas/uso terapêutico Comprimidos [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Bacterial Agents); 0 (Rifamycins); 0 (Tablets); L36O5T016N (rifaximin) [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171016 [Lr] Data última revisão: 171016 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170620 [St] Status: MEDLINE [do] DOI: 10.1254/fpj.149.288

7 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28522790 [Au] Autor: Banasiewicz T; Francuzik W; Bobkiewicz A; Krokowicz L; Borejsza-Wysocki M; Paszkowski J; Studniarek A; Krokowicz P; Grochowalski M; Szczepkowski M; Lorenc Z [Ad] Endereço: Klinika Chirurgii Ogólnej, Endokrynologicznej i Onkologii Gastroenterologicznej, Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu Panstwowa Wyzsza Szkola Zawodowa im. Prezydenta Stanislawa Wojciechowskiego w Kaliszu. [Ti] Título: The influence of rifaximin on diverticulitis rate and quality of life in patients with diverticulosis. [So] Source: Pol Przegl Chir;89(1):22-31, 2017 Feb 28. [Is] ISSN: 2299-2847 [Cp] País de publicação: Poland [La] Idioma: eng [Ab] Resumo: Diverticulosis, its associated symptoms and complications are one of the most common pathologies of the gastrointestinal tract in more economically developed countries. Presence of diverticuli and their clinical consequences can be divided into four categories: 1) diverticulosis, i.e. an asymptomatic presence of diverticuli that are usually found by accident 2) symptomatic uncomplicated diverticulosis 3) diverticulitis (acute uncomplicated diverticulitis) 4) complications of diverticulitis (conditions requiring hospital stay). The aim of this study was to retrospectively analyze the efficacy of rifaximin in preventing diverticulitis in patients visiting proctology clinics. The diagnostic criterium for diverticulosis was confirmation by colonoscopy, barium enema or CT colography (virtual colonoscopy) as well as history of at least one documented episode of diverticulosis. History of diverticulosis was evaluated based on medical records, clinical symptoms, elevated level of CRP (>5.0) and/or diagnostic imaging (ultrasound, CT). After setting strict exclusion criteria, 248 patients were qualified for the study out of 686, and they were later divided into two groups: control group (group I - 145 patients) and studied group (group II - 103 patients receiving rifaximin prophylaxis). Diverticulitis rate was comparable in both groups over a period of 6 months before study (p = 0.1306) and 6 months of treatment (p=0.3044). Between the 6th and 12th month of treatment, a significantly lower rate of diverticulitis was noted in the group receiving rifaximin compared to control group (p<0.0001). Patients receiving rifaximin reported higher quality of life (which was assessed using the VAS scale) compared to control group after 12 months. The results confirmed the efficacy of riaximin in prevention of diverticulitis, even in the scheme of repeated courses every 3 months. Not only did application of rifaximin lower the rate of diverticulitis and its complications in patients after an episode of diverticulitis, but also it improved the patients' quality of life. It seems that diverticulitis prophylaxis based on rifaximin can be economically efficient, however, it requires further research. [Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/uso terapêutico Doença Diverticular do Colo/tratamento farmacológico Fármacos Gastrointestinais/uso terapêutico Qualidade de Vida Rifamicinas/uso terapêutico [Mh] Termos MeSH secundário: Doença Diverticular do Colo/psicologia Feminino Seres Humanos Masculino Estudos Retrospectivos Índice de Gravidade de Doença Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Gastrointestinal Agents); 0 (Rifamycins); L36O5T016N (rifaximin) [Em] Mês de entrada: 1710 [Cu] Atualização por classe: 171004 [Lr] Data última revisão: 171004 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170520 [St] Status: MEDLINE [do] DOI: 10.5604/01.3001.0009.6012

8 / 1873

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 28387885 [Au] Autor: Festa V; Spila Alegiani S; Chiesara F; Moretti A; Bianchi M; Dezi A; Traversa G; Koch M [Ad] Endereço: Gastroenterology and Liver Unit, S. Filippo Neri General Hospital, Rome, Italy. virginia.festa@asl-rme.it. [Ti] Título: Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. [So] Source: Eur Rev Med Pharmacol Sci;21(6):1397-1404, 2017 Mar. [Is] ISSN: 2284-0729 [Cp] País de publicação: Italy [La] Idioma: eng [Ab] Resumo: OBJECTIVE: Diverticular disease (DD) of the colon has an increasing burden on health services. The effectiveness of rifaximin for the treatment of DD, is not yet established. The aim of this study is to assess the impact of long-term treatment with rifaximin or mesalazine in a 10-day schedule for the prevention of recurrent diverticulitis. PATIENTS AND METHODS: This is a retrospective study. We identified all consecutive patients with DD and previous acute diverticulitis (AD) in our outpatients' database; 124 patients, were included. The recommended therapy consisted of a ten-day/month treatment with either rifaximin (400 mg bid), or mesalazine (2.4 g/daily). Primary end point was AD recurrence. RESULTS: Between 2010 and 2014, 72 patients were treated with rifaximin and 52 with mesalazine. During a median follow-up of 15 months (range 1-50), we observed 21 episodes of AD among users of either rifaximin (n=7; 0.54 per 100 person-months), or mesalazine group (n=14; 1.46 per 100 person-months). Kaplan-Meier survival estimates of recurrent AD significantly differed between rifaximin and mesalazine groups (p=0.015). The multivariate Cox regression analysis showed that AD recurrence was significantly associated with therapy (rifaximin vs. mesalazine, adjusted HR 0.27; 95% CI: 0.10 to 0.72), age and gender. CONCLUSIONS: Long-term treatment with rifaximin in a 10-day schedule appears more effective than mesalazine in preventing recurrent AD. [Mh] Termos MeSH primário: Diverticulite/tratamento farmacológico Mesalamina/administração & dosagem Rifamicinas/administração & dosagem [Mh] Termos MeSH secundário: Adulto Idoso Idoso de 80 Anos ou mais Feminino Seres Humanos Masculino Meia-Idade Recidiva Estudos Retrospectivos Resultado do Tratamento [Pt] Tipo de publicação: COMPARATIVE STUDY; JOURNAL ARTICLE [Nm] Nome de substância: 0 (Rifamycins); 4Q81I59GXC (Mesalamine); L36O5T016N (rifaximin) [Em] Mês de entrada: 1708 [Cu] Atualização por classe: 170804 [Lr] Data última revisão: 170804 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170408 [St] Status: MEDLINE

9 / 1873

MEDLINE

seleciona para imprimir Fotocópia Texto completo

[PMID]: 28346018 [Au] Autor: Rabie H; Decloedt EH; Garcia-Prats AJ; Cotton MF; Frigati L; Lallemant M; Hesseling A; Schaaf HS [Ad] Endereço: a Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences , Stellenbosch University and Tygerberg Hospital , Cape Town , South Africa. [Ti] Título: Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis. [So] Source: Expert Opin Pharmacother;18(6):589-598, 2017 Apr. [Is] ISSN: 1744-7666 [Cp] País de publicação: England [La] Idioma: eng [Ab] Resumo: INTRODUCTION: In high prevalence settings, tuberculosis and HIV dual infection and co-treatment is frequent. Rifamycins, especially rifampicin, in combination with isoniazid, ethambutol and pyrazinamide are key components of short-course antituberculosis therapy. Areas covered: We reviewed available data, for which articles were identified by a Pubmed search, on rifamycin-antiretroviral interactions in HIV-infected children. Rifamycins have potent inducing effects on phase I and II drug metabolising enzymes and transporters. Antiretroviral medications are often metabolised by the enzymes induced by rifamycins or may suppress specific enzyme activity leading to drug-drug interactions with rifamycins. These may cause significant alterations in their phamacokinetic and pharmacodynamic properties, and sometimes that of the rifamycin. Recommended strategies to adapt to these interactions include avoidance and dose adjustment. Expert opinion: Despite the importance and frequency of tuberculosis as an opportunistic disease in HIV-infected children, current data on the management of co-treated children is based on few studies. We need new strategies to rapidly assess the use of rifamycins, new anti-tuberculosis drugs and antiretroviral drugs together as information on safety and dosing of individual drugs becomes available. [Mh] Termos MeSH primário: Fármacos Anti-HIV/uso terapêutico Infecções por HIV/tratamento farmacológico Tuberculose/tratamento farmacológico [Mh] Termos MeSH secundário: Antituberculosos/uso terapêutico Criança Interações Medicamentosas Seres Humanos Rifamicinas/uso terapêutico [Pt] Tipo de publicação: JOURNAL ARTICLE; REVIEW [Nm] Nome de substância: 0 (Anti-HIV Agents); 0 (Antitubercular Agents); 0 (Rifamycins) [Em] Mês de entrada: 1704 [Cu] Atualização por classe: 170417 [Lr] Data última revisão: 170417 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170328 [St] Status: MEDLINE [do] DOI: 10.1080/14656566.2017.1309023

10 / 1873

MEDLINE

seleciona para imprimir Fotocópia

[PMID]: 28338174 [Au] Autor: Mariani M; Zuccaro V; Patruno SF; Scudeller L; Sacchi P; Lombardi A; Vecchia M; Columpsi P; Marone P; Filice G; Bruno R [Ad] Endereço: Department of Infectious Diseases, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. raffaele.bruno@unipv.it. [Ti] Título: The impact of rifaximin in the prevention of bacterial infections in cirrhosis. [So] Source: Eur Rev Med Pharmacol Sci;21(5):1151-1158, 2017 Mar. [Is] ISSN: 2284-0729 [Cp] País de publicação: Italy [La] Idioma: eng [Ab] Resumo: OBJECTIVE: Bacterial infections are a leading factor in the progression from compensated to decompensated cirrhosis, with consequent worsening of the prognosis, and concerted efforts have been made to reduce infections and improve the survival rate of these patients. We retrospectively investigated the rate of infections in hospitalized cirrhotic patients under treatment with rifaximin. PATIENTS AND METHODS: We enrolled 649 patients whose clinical and personal data, prescribed therapy, microbiological findings and laboratory tests were collected from previous discharge letters and our institution database. The efficacy of rifaximin in preventing several types infection was evaluated by comparing outcomes for rifaximin-treated patients vs patients receiving no antibiotic treatment. RESULTS: The risk of developing selected bacterial infections was significantly lower in patients treated with rifaximin (OR 0.29; 95% CI 0.20-0.40, p < 0.001). CONCLUSIONS: Continuous treatment with rifaximin may prevent bacterial infections in cirrhotic patients. [Mh] Termos MeSH primário: Anti-Infecciosos/uso terapêutico Infecções Bacterianas/prevenção & controle Cirrose Hepática/complicações Rifamicinas/uso terapêutico [Mh] Termos MeSH secundário: Infecções Bacterianas/complicações Seres Humanos Resultado do Tratamento [Pt] Tipo de publicação: JOURNAL ARTICLE [Nm] Nome de substância: 0 (Anti-Infective Agents); 0 (Rifamycins); L36O5T016N (rifaximin) [Em] Mês de entrada: 1707 [Cu] Atualização por classe: 170726 [Lr] Data última revisão: 170726 [Sb] Subgrupo de revista: IM [Da] Data de entrada para processamento: 170325 [St] Status: MEDLINE

---

página 1 de 188

ir para página

Refinar a pesquisa

Base de dados : MEDLINE

Formulário avançado

		Pesquisar	no campo
1			PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
2	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2
3	and or and not		PalavrasDescritor de assuntoDescritor de assunto primárioLimitesAutorPalavras do títuloPalavras do resumoIdiomaPaís de publicaçãoNome de substânciaNome de pessoa como assuntoRevistaAssunto de RevistaISSNTipo de publicaçãoIdentificador únicoMês de entradaAno de publicaçãoTexto completoAtualização por classeCategoria DeCSCategoria DeCS explodidaCategoria CID-10SubSetsPais de AfiliaçãoAfiliaçãoAfiliação 2

Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde